Immune Response to COVID-19 Vaccination in Hematologic Malignancies: A Mini-Review

The outbreak of the COVID-19 infection has led to the rapidity of vaccine usage in recent years. Emerging data indicate that the efficacy of vaccination against COVID-19 was about 95% in the general population, though its impact is impaired in patients with hematologic malignancies. As such, we deci...

Descripción completa

Detalles Bibliográficos
Autores principales: Keshavarz, Samaneh, Keshavarz, Somayeh, Ziamajidi, Nasrin, Daei, Sajedeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chonnam National University Medical School 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900228/
https://www.ncbi.nlm.nih.gov/pubmed/36794237
http://dx.doi.org/10.4068/cmj.2023.59.1.24
Descripción
Sumario:The outbreak of the COVID-19 infection has led to the rapidity of vaccine usage in recent years. Emerging data indicate that the efficacy of vaccination against COVID-19 was about 95% in the general population, though its impact is impaired in patients with hematologic malignancies. As such, we decided to research the publications in which the authors reported the impacts of COVID-19 vaccination in patients suffering from hematologic malignancies. We concluded that patients with hematologic malignancies have lower responses, antibody titers as well as an impaired humoral response following vaccination, notably in patients with chronic lymphocytic leukemia (CLL) and lymphoma. Furthermore, it seems that the status of treatment can significantly affect the responses to the COVID-19 vaccination.

Ejemplares similares